{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:06:18Z","timestamp":1790723178196,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["li.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Laboratory Investigation"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.labinv.2026.106136","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:46:11Z","timestamp":1779205571000},"page":"106136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunohistochemical Assay Variability and Human Epidermal Growth Factor Receptor 2 (HER2)-Low Breast Cancer Detection: A Laboratory Comparison in the Netherlands"],"prefix":"10.1016","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0092-2884","authenticated-orcid":false,"given":"Zeynep E.","family":"Kain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Schuurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximena","family":"Baez-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"H\u00f8eg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanth","family":"Kanneganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils \u2019t","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolien H.M.","family":"van Deurzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.labinv.2026.106136_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"10.1016\/j.labinv.2026.106136_bib2","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1245\/s10434-018-6486-6","article-title":"Eighth edition of the AJCC cancer staging manual: breast cancer","volume":"25","author":"Giuliano","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"16","key":"10.1016\/j.labinv.2026.106136_bib3","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.labinv.2026.106136_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.labinv.2026.106136_bib5","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.labinv.2026.106136_bib6","first-page":"159","article-title":"FDA approves TROP2-targeted antibody-drug conjugate for breast cancer","volume":"24","author":"Mullard","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.labinv.2026.106136_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105919","article-title":"New standards in HER2-low testing: the CASI-01 comparative methods study","volume":"120","author":"Dabbs","year":"2025","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.labinv.2026.106136_bib9","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41379-021-00884-w","article-title":"Quantitative comparison of PD-L1 IHC assays against NIST standard reference material 1934","volume":"35","author":"Sompuram","year":"2022","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.labinv.2026.106136_bib10","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1369\/0022155415588109","article-title":"Standardizing immunohistochemistry: a new reference control for detecting staining problems","volume":"63","author":"Sompuram","year":"2015","journal-title":"J Histochem Cytochem"},{"issue":"7","key":"10.1016\/j.labinv.2026.106136_bib11","doi-asserted-by":"crossref","first-page":"851","DOI":"10.5858\/arpa.2017-0330-OA","article-title":"Quantitative assessment of immunohistochemistry laboratory performance by measuring analytic response curves and limits of detection","volume":"142","author":"Sompuram","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"10.1016\/j.labinv.2026.106136_bib12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1369\/0022155418824092","article-title":"Selecting an optimal positive IHC control for verifying antigen retrieval","volume":"67","author":"Sompuram","year":"2019","journal-title":"J Histochem Cytochem"},{"issue":"3","key":"10.1016\/j.labinv.2026.106136_bib13","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.prp.2015.11.016","article-title":"Interobserver reproducibility for HER2\/neu immunohistochemistry: a comparison of reproducibility for the HercepTest\u2122 and the 4B5 antibody clone","volume":"212","author":"Layfield","year":"2016","journal-title":"Pathol Res Pract"},{"issue":"5","key":"10.1016\/j.labinv.2026.106136_bib14","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00428-022-03378-5","article-title":"Comparison of HercepTest\u2122 mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2\/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status","volume":"481","author":"R\u00fcschoff","year":"2022","journal-title":"Virchows Arch"},{"issue":"5","key":"10.1016\/j.labinv.2026.106136_bib15","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ajcp\/aqac184","article-title":"Interobserver and interantibody reproducibility of HER2 immunohistochemical scoring in an enriched HER2-low-expressing breast cancer cohort","volume":"159","author":"Karakas","year":"2023","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.labinv.2026.106136_bib16","article-title":"HER2-low breast cancer in routine practice: a nationwide study of diagnostic variability across pathology laboratories","author":"Kain","year":"2025","journal-title":"Virchows Arch"},{"issue":"1","key":"10.1016\/j.labinv.2026.106136_bib17","first-page":"19","article-title":"Pathology databanking and biobanking in the Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive","volume":"29","author":"Casparie","year":"2007","journal-title":"Cell Oncol"},{"issue":"22","key":"10.1016\/j.labinv.2026.106136_bib19","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.labinv.2026.106136_bib20","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/his.15273","article-title":"Quantitative comparison of immunohistochemical HER2-low detection in an interlaboratory study","volume":"85","author":"Hempenius","year":"2024","journal-title":"Histopathology"},{"issue":"8 Suppl","key":"10.1016\/j.labinv.2026.106136_bib21","first-page":"4244s","article-title":"Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors","volume":"46","author":"McCarty","year":"1986","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.labinv.2026.106136_bib22","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/clinchem\/hvab008","article-title":"Development and validation of measurement traceability for in situ immunoassays","volume":"67","author":"Torlakovic","year":"2021","journal-title":"Clin Chem"},{"issue":"10","key":"10.1016\/j.labinv.2026.106136_bib23","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/PAI.0000000000001230","article-title":"Comparing the sensitivity of HER2 epitope detection of herceptest mAb pharmDx (Dako Omnis, GE001) and ventana pathway anti-HER-2\/neu (4B5) using IHC calibrators","volume":"32","author":"Aidt","year":"2024","journal-title":"Appl Immunohistochem Mol Morphol"}],"container-title":["Laboratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683726000668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683726000668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:14:10Z","timestamp":1790378050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0023683726000668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0023683726000668"],"URL":"https:\/\/doi.org\/10.1016\/j.labinv.2026.106136","relation":{},"ISSN":["0023-6837"],"issn-type":[{"value":"0023-6837","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunohistochemical Assay Variability and Human Epidermal Growth Factor Receptor 2 (HER2)-Low Breast Cancer Detection: A Laboratory Comparison in the Netherlands","name":"articletitle","label":"Article Title"},{"value":"Laboratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.labinv.2026.106136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}],"article-number":"106136"}}